Ophthalmology Times

CONTINUE TO SITE

OR WAIT null SECS

Cataract Therapeutics EyeCon'21 Presbyopia Retina Drug Delivery Glaucoma Insights CME Activities Dry Eye Viewpoint Diabetic Eye Disease Viewpoints Cornea Updates Diabetic Eye Disease Podcast DME Therapy Dry Eye Concepts Dry Eye Flares Eyevance Case Studies Management of Dry Eye Viewpoints Ptosis WetAMD Viewpoints

Cataract Therapeutics EyeCon'21 Presbyopia Retina Drug Delivery Glaucoma Insights CME Activities Dry Eye Viewpoint Diabetic Eye Disease Viewpoints Cornea Updates Diabetic Eye Disease Podcast DME Therapy Dry Eye Concepts Dry Eye Flares Eyevance Case Studies Management of Dry Eye Viewpoints Ptosis WetAMD Viewpoints

View More Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

All News Blogs COVID-19

Expert Interviews

Medical World News

Expert Interviews Medical World News Podcasts Viewpoints Insights Eyeviews Case Studies

Health Law & Policy

Personal Finance

Practice Management

Health Law & Policy Money Matters Personal Finance Practice Management

Conference Coverage

Conference Listing

Conference Recaps

Conference Coverage Conference Listing Conference Recaps

Digital Edition

Europe Ophthalmology Times

Supplements and Featured Publications

Digital Edition Europe Ophthalmology Times Modern Retina Supplements and Featured Publications

Partners CME/CE Job Board Sponsored

Print Subscription

eNewsletter Print Subscription

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Ophthalmology Times. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Cataract Therapeutics
EyeCon'21
Presbyopia
Retina Drug Delivery
Glaucoma Insights
CME Activities
Dry Eye Viewpoint
Diabetic Eye Disease Viewpoints
Cornea Updates
Diabetic Eye Disease Podcast
DME Therapy
Dry Eye Concepts
Dry Eye Flares
Eyevance Case Studies
Management of Dry Eye Viewpoints
Ptosis
WetAMD Viewpoints

ClinicalSee All >

Cataract
Clinical Diagnosis
Cornea
Glaucoma
IOL
OCT
Ocular Allergy
Ocular Surface Disease
Pediatrics
Refractive
Retina
Technology
Therapeutic Cataract & Refractive
Understanding Antibiotic Resistance

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences^™ and Ophthalmology Times. All rights reserved.

ISTA begins phase III study of bromfenac

July 1, 2003

ISTA Pharmaceuticals Inc. has filed an investigational new drug application with the FDA to begin a phase III study of bromfenac.

Related Content:

ImprimisRx offers a look at three new products in the pipeline

ImprimisRx offers a look at three new products in the pipeline

Making the grade: FDA approves first biosimilar product for retinal diseases

Making the grade: FDA approves first biosimilar product for retinal diseases

Advancement in TED treatment is a bright spot

Advancement in TED treatment is a bright spot